Insmed Announces Pricing of Public Offering of Convertible Senior Notes


Insmed Incorporated announced today that it priced its registered underwritten public offering of $400 million aggregate principal amount of its 1.75% convertible senior notes due 2025. Net proceeds from the offering, after deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $387.3 million.



from Biotech News